Current Therapies Focused on High-Density Lipoproteins Associated with Cardiovascular Disease
High-density lipoproteins (HDL) comprise a heterogeneous family of lipoprotein particles divided into subclasses that are determined by density, size and surface charge as well as protein composition. Epidemiological studies have suggested an inverse correlation between High-density lipoprotein-chol...
| Main Authors: | , , , , , , , , , |
|---|---|
| Format: | Article |
| Language: | English |
| Published: |
MDPI AG
2018-10-01
|
| Series: | Molecules |
| Subjects: | |
| Online Access: | https://www.mdpi.com/1420-3049/23/11/2730 |
| _version_ | 1818153602048327680 |
|---|---|
| author | Diego Estrada-Luna María Araceli Ortiz-Rodriguez Lizett Medina-Briseño Elizabeth Carreón-Torres Jeannett Alejandra Izquierdo-Vega Ashutosh Sharma Juan Carlos Cancino-Díaz Oscar Pérez-Méndez Helen Belefant-Miller Gabriel Betanzos-Cabrera |
| author_facet | Diego Estrada-Luna María Araceli Ortiz-Rodriguez Lizett Medina-Briseño Elizabeth Carreón-Torres Jeannett Alejandra Izquierdo-Vega Ashutosh Sharma Juan Carlos Cancino-Díaz Oscar Pérez-Méndez Helen Belefant-Miller Gabriel Betanzos-Cabrera |
| author_sort | Diego Estrada-Luna |
| collection | DOAJ |
| description | High-density lipoproteins (HDL) comprise a heterogeneous family of lipoprotein particles divided into subclasses that are determined by density, size and surface charge as well as protein composition. Epidemiological studies have suggested an inverse correlation between High-density lipoprotein-cholesterol (HDL-C) levels and the risk of cardiovascular diseases and atherosclerosis. HDLs promote reverse cholesterol transport (RCT) and have several atheroprotective functions such as anti-inflammation, anti-thrombosis, and anti-oxidation. HDLs are considered to be atheroprotective because they are associated in serum with paraoxonases (PONs) which protect HDL from oxidation. Polyphenol consumption reduces the risk of chronic diseases in humans. Polyphenols increase the binding of HDL to PON1, increasing the catalytic activity of PON1. This review summarizes the evidence currently available regarding pharmacological and alternative treatments aimed at improving the functionality of HDL-C. Information on the effectiveness of the treatments has contributed to the understanding of the molecular mechanisms that regulate plasma levels of HDL-C, thereby promoting the development of more effective treatment of cardiovascular diseases. For that purpose, Scopus and Medline databases were searched to identify the publications investigating the impact of current therapies focused on high-density lipoproteins. |
| first_indexed | 2024-12-11T14:13:13Z |
| format | Article |
| id | doaj.art-34fc15dfe6f04ec995b89171db908ff0 |
| institution | Directory Open Access Journal |
| issn | 1420-3049 |
| language | English |
| last_indexed | 2024-12-11T14:13:13Z |
| publishDate | 2018-10-01 |
| publisher | MDPI AG |
| record_format | Article |
| series | Molecules |
| spelling | doaj.art-34fc15dfe6f04ec995b89171db908ff02022-12-22T01:03:18ZengMDPI AGMolecules1420-30492018-10-012311273010.3390/molecules23112730molecules23112730Current Therapies Focused on High-Density Lipoproteins Associated with Cardiovascular DiseaseDiego Estrada-Luna0María Araceli Ortiz-Rodriguez1Lizett Medina-Briseño2Elizabeth Carreón-Torres3Jeannett Alejandra Izquierdo-Vega4Ashutosh Sharma5Juan Carlos Cancino-Díaz6Oscar Pérez-Méndez7Helen Belefant-Miller8Gabriel Betanzos-Cabrera9Instituto Nacional de Cardiología “Ignacio Chávez” Juan Badiano No. 1, Belisario Domínguez Sección 16, 14080 Tlalpan, Mexico City, MexicoFacultad de Nutrición, Universidad Autónoma del Estado de Morelos, UAEM, Calle Río Iztaccihuatl S/N, Vista Hermosa, 62350 Cuernavaca, Morelos, MexicoUniversidad de la Sierra Sur, UNSIS, Miahuatlán de Porfirio Díaz, 70800 Oaxaca, MexicoInstituto Nacional de Cardiología “Ignacio Chávez” Juan Badiano No. 1, Belisario Domínguez Sección 16, 14080 Tlalpan, Mexico City, MexicoÁrea Académica de Medicina, Instituto de Ciencias de la Salud, Universidad Autónoma del Estado de Hidalgo, Carretera Actopan-Tilcuautla, Ex-Hacienda La Concepción S/N, San Agustín Tlaxiaca, 42160 Hidalgo, MexicoTecnologico de Monterrey, School of Engineering and Sciences, Campus Queretaro, Epigmenio Gonzalez 500, 76130 Queretaro, MexicoDepartamento de Microbiología, Escuela Nacional de Ciencias Biológicas del Instituto Politécnico Nacional, 11340 Ciudad de México, MexicoInstituto Nacional de Cardiología “Ignacio Chávez” Juan Badiano No. 1, Belisario Domínguez Sección 16, 14080 Tlalpan, Mexico City, MexicoDale Bumpers National Rice Research Center, Stuttgart, AR 72160, USAÁrea Académica de Medicina, Instituto de Ciencias de la Salud, Universidad Autónoma del Estado de Hidalgo, Carretera Actopan-Tilcuautla, Ex-Hacienda La Concepción S/N, San Agustín Tlaxiaca, 42160 Hidalgo, MexicoHigh-density lipoproteins (HDL) comprise a heterogeneous family of lipoprotein particles divided into subclasses that are determined by density, size and surface charge as well as protein composition. Epidemiological studies have suggested an inverse correlation between High-density lipoprotein-cholesterol (HDL-C) levels and the risk of cardiovascular diseases and atherosclerosis. HDLs promote reverse cholesterol transport (RCT) and have several atheroprotective functions such as anti-inflammation, anti-thrombosis, and anti-oxidation. HDLs are considered to be atheroprotective because they are associated in serum with paraoxonases (PONs) which protect HDL from oxidation. Polyphenol consumption reduces the risk of chronic diseases in humans. Polyphenols increase the binding of HDL to PON1, increasing the catalytic activity of PON1. This review summarizes the evidence currently available regarding pharmacological and alternative treatments aimed at improving the functionality of HDL-C. Information on the effectiveness of the treatments has contributed to the understanding of the molecular mechanisms that regulate plasma levels of HDL-C, thereby promoting the development of more effective treatment of cardiovascular diseases. For that purpose, Scopus and Medline databases were searched to identify the publications investigating the impact of current therapies focused on high-density lipoproteins.https://www.mdpi.com/1420-3049/23/11/2730lipoproteinsHDL-Cparaoxonasepolyphenols |
| spellingShingle | Diego Estrada-Luna María Araceli Ortiz-Rodriguez Lizett Medina-Briseño Elizabeth Carreón-Torres Jeannett Alejandra Izquierdo-Vega Ashutosh Sharma Juan Carlos Cancino-Díaz Oscar Pérez-Méndez Helen Belefant-Miller Gabriel Betanzos-Cabrera Current Therapies Focused on High-Density Lipoproteins Associated with Cardiovascular Disease Molecules lipoproteins HDL-C paraoxonase polyphenols |
| title | Current Therapies Focused on High-Density Lipoproteins Associated with Cardiovascular Disease |
| title_full | Current Therapies Focused on High-Density Lipoproteins Associated with Cardiovascular Disease |
| title_fullStr | Current Therapies Focused on High-Density Lipoproteins Associated with Cardiovascular Disease |
| title_full_unstemmed | Current Therapies Focused on High-Density Lipoproteins Associated with Cardiovascular Disease |
| title_short | Current Therapies Focused on High-Density Lipoproteins Associated with Cardiovascular Disease |
| title_sort | current therapies focused on high density lipoproteins associated with cardiovascular disease |
| topic | lipoproteins HDL-C paraoxonase polyphenols |
| url | https://www.mdpi.com/1420-3049/23/11/2730 |
| work_keys_str_mv | AT diegoestradaluna currenttherapiesfocusedonhighdensitylipoproteinsassociatedwithcardiovasculardisease AT mariaaraceliortizrodriguez currenttherapiesfocusedonhighdensitylipoproteinsassociatedwithcardiovasculardisease AT lizettmedinabriseno currenttherapiesfocusedonhighdensitylipoproteinsassociatedwithcardiovasculardisease AT elizabethcarreontorres currenttherapiesfocusedonhighdensitylipoproteinsassociatedwithcardiovasculardisease AT jeannettalejandraizquierdovega currenttherapiesfocusedonhighdensitylipoproteinsassociatedwithcardiovasculardisease AT ashutoshsharma currenttherapiesfocusedonhighdensitylipoproteinsassociatedwithcardiovasculardisease AT juancarloscancinodiaz currenttherapiesfocusedonhighdensitylipoproteinsassociatedwithcardiovasculardisease AT oscarperezmendez currenttherapiesfocusedonhighdensitylipoproteinsassociatedwithcardiovasculardisease AT helenbelefantmiller currenttherapiesfocusedonhighdensitylipoproteinsassociatedwithcardiovasculardisease AT gabrielbetanzoscabrera currenttherapiesfocusedonhighdensitylipoproteinsassociatedwithcardiovasculardisease |